Stay updated on ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial
Sign up to get notified when there's something new on the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page.

Latest updates to the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page’s “Revision” (site/system version) label was updated from v3.5.0 to v3.5.3, reflecting a backend or platform update rather than a change to the displayed study results.SummaryDifference0.0%

- Check38 days agoChange DetectedKey results data and descriptions were removed from the Study Results page, including participant counts by timepoint and arm, and several primary/secondary outcomes (LDL-C, PCSK9, triglycerides, ApoB) along with adverse events.SummaryDifference0.9%

- Check45 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0; this appears to be a versioning change rather than substantive content updates.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check87 days agoChange DetectedRevision: v3.4.2 is added and updated results sections include Absolute Change in PCSK9 Levels From Baseline for ORION-3 at Days 30, 360, 720 and 1440 with corresponding participants. LDL-C and related outcome data points have been updated or clarified, and arm descriptions/timeframes are explained.SummaryDifference0.2%

- Check94 days agoChange DetectedNew results data were added, including Mean (95% CI) values, units (ug/L), and timepoint-specific LDL-C and PCSK9 changes with participant counts. A government funding notice regarding potential delays and the NIH Clinical Center's status was also added.SummaryDifference0.2%

Stay in the know with updates to ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page.